Human Oncology & Pathogenesis Program
The Michael Berger Lab
Research
The focus of the Berger laboratory is to use novel computational and experimental techniques to characterize the spectrum of genetic mutations in human tumors in order to identify biomarkers of cancer progression and drug response.
The identification of molecular drivers of cancer and the development of targeted therapies for these drivers offer hope for better outcomes for patients with cancer. Global efforts to comprehensively characterize the genomes of all major cancer types continue to reveal new genetic alterations with implications for tumor biology, prognosis, and treatment. Using massively parallel next-generation DNA sequencing, we are developing and applying methods of profiling individual tumor specimenspatient biospecimens for somatic base mutations and other genomicand inherited alterations that may influence response to therapy. Our research falls into two main categories: technology development and biomarker discovery.
Featured News
Publications
People
Michael F. Berger, PhD
Co-Director, Marie-Josée & Henry R. Kravis Center for Molecular Oncology; Attending, Molecular Diagnostics Service, Department of Pathology
- Researcher Michael Berger focuses on massively parallel sequencing of tumor DNA for biomarker discovery and clinical diagnostics.
- PhD, Harvard University
- bergerm1@mskcc.org
- Email Address
- 646-888-3386
- Office Phone
- View physician profile
- Physician profile
Members
Lab Alumni
Open Positions
To learn more about available postdoctoral opportunities, please visit our Career Center
Career Opportunities
Get in Touch
-
Lab Head Email
-
Office Phone
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Michael F. Berger discloses the following relationships and financial interests:
-
Advances in Genome Biology and Technology (AGBT)
Provision of Services (uncompensated) -
American Society of Clinical Oncology (ASCO)
Provision of Services -
Eli Lilly and Company
Provision of Services -
JCO Precision Oncology
Provision of Services (uncompensated)
-
Journal of Molecular Diagnostics
Provision of Services (uncompensated) -
Journal of Visualized Experiments
Provision of Services (uncompensated) -
PetDx, Inc.
Provision of Services
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.